All contributors
Onconephrology contributor
Kitchlu, Abhijat
Primarily Anticancer drug nephrotoxicity#23 of 47 recognizedHonor roll
- #5 in Onco-nephrology (general)
28
Clinical papers
1,547
Citations (iCite)
5 / 10
First / senior author
2017–2026
Active years
Output over time
Clinical corpus papers per year — peak 7 in 2024.
- 2017: 2 papers
- 2019: 3 papers
- 2020: 2 papers
- 2021: 5 papers
- 2022: 4 papers
- 2023: 1 paper
- 2024: 7 papers
- 2025: 2 papers
- 2026: 2 papers
20172026
Subfield mix
Clinical papers by onconephrology subfield (a paper can count in more than one).
Anticancer drug nephrotoxicity20
Checkpoint-inhibitor kidney injury9
Onco-nephrology (general)7
Cellular therapy renal effects2
Myeloma cast nephropathy2
Anti-VEGF / TKI renal effects1
MGRS & paraprotein kidney disease1
Frequent collaborators
Other recognized contributors who most often share corpus papers with Kitchlu (shared-paper count).
Agents they study
Catalog agents whose clinical kidney literature lists Kitchlu among the leading contributors.
Verify
Representative recent papers, and this author’s full PubMed bibliography.
A code-tallied bibliometric profile from PubMed + NIH iCite, restricted to human/clinical papers across a 15,329-article corpus (regenerated 2026-08-02). Recognition of published contribution — not a verdict on merit or influence, and not medical advice.